2020
DOI: 10.1080/20905068.2020.1714191
|View full text |Cite
|
Sign up to set email alerts
|

Evaluation of serum kallistatin level as a predictor of esophageal varices in cirrhotic patients

Abstract: Introduction: The Baveno VI consensus recommended the use of noninvasive predictors to identify patients at high risk of esophageal varices (EV) in whom endoscopic evaluation is most needed. Kallistatin is a protein molecule synthesized by the liver, and its level declines with the deterioration of liver functions. We aim to explore the role of kallistatin as a predictor of esophageal varices. Methods: This case-control study included 70 cirrhotic patients (35 patients with EV and 35 patients without EV). The … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

1
1
0

Year Published

2022
2022
2022
2022

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(2 citation statements)
references
References 23 publications
1
1
0
Order By: Relevance
“…Our study showed that serum kallistatin levels in patients with liver fibrosis were significantly lower than those in healthy controls, demonstrating a correlation between the reduction in serum kallistatin levels and the severity of liver disease. This finding was similar to previous studies done by Sobhey et al ,[ 20 ] Elsaeed et al ,[ 21 ] Cheng et al ,[ 22 ] and Chao et al . [ 23 ] Therefore, serum kallistatin levels can provide an additional biomarker for the detection of progressive loss of liver function leading to liver fibrosis and portal hypertension.…”
Section: Discussionsupporting
confidence: 94%
See 1 more Smart Citation
“…Our study showed that serum kallistatin levels in patients with liver fibrosis were significantly lower than those in healthy controls, demonstrating a correlation between the reduction in serum kallistatin levels and the severity of liver disease. This finding was similar to previous studies done by Sobhey et al ,[ 20 ] Elsaeed et al ,[ 21 ] Cheng et al ,[ 22 ] and Chao et al . [ 23 ] Therefore, serum kallistatin levels can provide an additional biomarker for the detection of progressive loss of liver function leading to liver fibrosis and portal hypertension.…”
Section: Discussionsupporting
confidence: 94%
“…As compared to our study, which showed serum kallistatin levels of 0.171 mg/mL, a study done by Sobhey et al . in 2020[ 20 ] showed kallistatin levels ranged between 1.8 and 17.8 mg/mL in cirrhotic patients with esophageal varices and between 10.3 and 32.5 mg/mL in cirrhotic patients without varices. Similarly, in a study done by Cheng et al ,[ 22 ] it was 16.78 ± 8.65 mg/mL.…”
Section: Discussionmentioning
confidence: 99%